This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Grazax Asthma Prevention (GAP)

This study has been completed.
Information provided by (Responsible Party):
ALK-Abelló A/S Identifier:
First received: February 1, 2010
Last updated: September 7, 2016
Last verified: September 2016
Investigation of the effect of Grazax (grass tablet) on asthma prevention in children with grass pollen allergy

Condition Intervention Phase
Allergic Rhinitis Drug: Grazax Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Grazax Asthma Prevention

Further study details as provided by ALK-Abelló A/S:

Primary Outcome Measures:
  • Evaluation of allergy and asthma symptoms [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Quality of life and adverse events [ Time Frame: 5 years ]

Enrollment: 812
Study Start Date: January 2010
Study Completion Date: September 2015
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Grazax
Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
Drug: Grazax
Treatment with 75.000 SQ-T once daily
Placebo Comparator: Tablet with no active grass
Tablet with no active grass component. One tablet per day administered under the tongue.
Drug: Placebo
Tablet with no active grass component.

Detailed Description:

Investigation of the effect of Grazax (ALK produced grass tablet) on asthma prevention in children with grass pollen allergy.

Children in the age of 6-12 years will be randomised to either placebo or Grazax treatment. Grazax has been approved for treatment of grass pollen allergy in adults and children, diagnosed with a positive skin prick test and/or specific immunoglobulin (IgE) test to grass pollen and with clinically relevant symptoms. This study will explore prevention of asthma in children with grass pollen induced allergy.


Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A history of grass pollen allergy
  • Positive Skin prick test to grass
  • Positive specific IgE to grass

Exclusion Criteria:

  • Asthma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01061203

Terveystalo Turku
Turku, Finland, 20100
Sponsors and Collaborators
ALK-Abelló A/S
Principal Investigator: Erkka Valovirta, MD Terveystalo Turku, Finland
  More Information

Responsible Party: ALK-Abelló A/S Identifier: NCT01061203     History of Changes
Other Study ID Numbers: GT-21
Study First Received: February 1, 2010
Last Updated: September 7, 2016

Keywords provided by ALK-Abelló A/S:

Additional relevant MeSH terms:
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on September 19, 2017